vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
BALCHEM CORP is the larger business by last-quarter revenue ($270.7M vs $164.7M, roughly 1.6× PTC THERAPEUTICS, INC.). BALCHEM CORP runs the higher net margin — 14.9% vs -82.0%, a 96.8% gap on every dollar of revenue. On growth, BALCHEM CORP posted the faster year-over-year revenue change (8.1% vs -22.7%). BALCHEM CORP produced more free cash flow last quarter ($33.8M vs $-36.6M). Over the past eight quarters, BALCHEM CORP's revenue compounded faster (7.5% CAGR vs -11.5%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
BCPC vs PTCT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.7M | $164.7M |
| Net Profit | $40.3M | $-135.0M |
| Gross Margin | — | — |
| Operating Margin | 20.5% | -43.3% |
| Net Margin | 14.9% | -82.0% |
| Revenue YoY | 8.1% | -22.7% |
| Net Profit YoY | 8.7% | -104.8% |
| EPS (diluted) | $1.25 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $270.7M | — | ||
| Q4 25 | $263.6M | $164.7M | ||
| Q3 25 | $267.6M | $211.0M | ||
| Q2 25 | $255.5M | $178.9M | ||
| Q1 25 | $250.5M | $1.2B | ||
| Q4 24 | $240.0M | $213.2M | ||
| Q3 24 | $239.9M | $196.8M | ||
| Q2 24 | $234.1M | $186.7M |
| Q1 26 | $40.3M | — | ||
| Q4 25 | $39.2M | $-135.0M | ||
| Q3 25 | $40.3M | $15.9M | ||
| Q2 25 | $38.3M | $-64.8M | ||
| Q1 25 | $37.1M | $866.6M | ||
| Q4 24 | $33.6M | $-65.9M | ||
| Q3 24 | $33.8M | $-106.7M | ||
| Q2 24 | $32.1M | $-99.2M |
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — |
| Q1 26 | 20.5% | — | ||
| Q4 25 | 19.8% | -43.3% | ||
| Q3 25 | 20.4% | 1.4% | ||
| Q2 25 | 20.1% | -19.5% | ||
| Q1 25 | 20.4% | 82.5% | ||
| Q4 24 | 19.8% | -76.2% | ||
| Q3 24 | 20.0% | -27.7% | ||
| Q2 24 | 19.6% | -21.5% |
| Q1 26 | 14.9% | — | ||
| Q4 25 | 14.9% | -82.0% | ||
| Q3 25 | 15.1% | 7.5% | ||
| Q2 25 | 15.0% | -36.3% | ||
| Q1 25 | 14.8% | 73.7% | ||
| Q4 24 | 14.0% | -30.9% | ||
| Q3 24 | 14.1% | -54.2% | ||
| Q2 24 | 13.7% | -53.1% |
| Q1 26 | $1.25 | — | ||
| Q4 25 | $1.21 | $-1.63 | ||
| Q3 25 | $1.24 | $0.20 | ||
| Q2 25 | $1.17 | $-0.83 | ||
| Q1 25 | $1.13 | $10.04 | ||
| Q4 24 | $1.03 | $-0.85 | ||
| Q3 24 | $1.03 | $-1.39 | ||
| Q2 24 | $0.98 | $-1.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $72.9M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $-205.3M |
| Total Assets | $1.7B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $72.9M | — | ||
| Q4 25 | $74.6M | $1.9B | ||
| Q3 25 | $65.1M | $1.7B | ||
| Q2 25 | $65.4M | $2.0B | ||
| Q1 25 | $49.9M | $2.0B | ||
| Q4 24 | $49.5M | $1.1B | ||
| Q3 24 | $73.7M | $1.0B | ||
| Q2 24 | $63.7M | $1.1B |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $-205.3M | ||
| Q3 25 | $1.3B | $-155.8M | ||
| Q2 25 | $1.3B | $-206.5M | ||
| Q1 25 | $1.2B | $-185.8M | ||
| Q4 24 | $1.1B | $-1.1B | ||
| Q3 24 | $1.2B | $-1.1B | ||
| Q2 24 | $1.1B | $-980.2M |
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $2.9B | ||
| Q3 25 | $1.7B | $2.6B | ||
| Q2 25 | $1.7B | $2.6B | ||
| Q1 25 | $1.6B | $2.7B | ||
| Q4 24 | $1.6B | $1.7B | ||
| Q3 24 | $1.6B | $1.8B | ||
| Q2 24 | $1.6B | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $40.1M | $-34.3M |
| Free Cash FlowOCF − Capex | $33.8M | $-36.6M |
| FCF MarginFCF / Revenue | 12.5% | -22.3% |
| Capex IntensityCapex / Revenue | 2.3% | 1.4% |
| Cash ConversionOCF / Net Profit | 0.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.1M | — | ||
| Q4 25 | $67.3M | $-34.3M | ||
| Q3 25 | $65.6M | $-66.3M | ||
| Q2 25 | $47.3M | $-58.3M | ||
| Q1 25 | $36.5M | $870.1M | ||
| Q4 24 | $52.3M | $-30.0M | ||
| Q3 24 | $51.3M | $-77.0M | ||
| Q2 24 | $45.0M | $-71.5M |
| Q1 26 | $33.8M | — | ||
| Q4 25 | — | $-36.6M | ||
| Q3 25 | — | $-69.7M | ||
| Q2 25 | — | $-59.6M | ||
| Q1 25 | — | $868.4M | ||
| Q4 24 | — | $-33.8M | ||
| Q3 24 | — | $-77.5M | ||
| Q2 24 | — | $-78.8M |
| Q1 26 | 12.5% | — | ||
| Q4 25 | — | -22.3% | ||
| Q3 25 | — | -33.1% | ||
| Q2 25 | — | -33.3% | ||
| Q1 25 | — | 73.8% | ||
| Q4 24 | — | -15.8% | ||
| Q3 24 | — | -39.4% | ||
| Q2 24 | — | -42.2% |
| Q1 26 | 2.3% | — | ||
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 4.0% |
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | -4.17× | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | 1.00× | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
